1-chloro-3,6-dioxa-8-octyl 2,4,6-tri-O-acetyl-β-D-galactoside | 274258-28-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-chloro-3,6-dioxa-8-octyl 2,4,6-tri-O-acetyl-β-D-galactoside
• 英文别名: 2-[2-(2-Chloroethoxy)ethoxy]ethyl 2,4,6-tri-O-acetyl β-D-galactopyranoside；[(2R,3R,4S,5R,6R)-3,5-diacetyloxy-6-[2-[2-(2-chloroethoxy)ethoxy]ethoxy]-4-hydroxyoxan-2-yl]methyl acetate
• CAS: 274258-28-5
• 化学式: C₁₈H₂₉ClO₁₁
• 分子量: 456.875
• InChiKey: IRTZSNGFIONMSD-DISONHOPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  30
• 可旋转键数：
  16
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  136
• 氢给体数：
  1
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  1-chloro-3,6-dioxa-8-octyl 2,4,6-tri-O-acetyl-β-D-galactoside 在 sodium azide 、 2,6-二叔丁基-4-甲基吡啶 、 4 A molecular sieve 、 三氟甲烷磺酸甲酯 作用下， 以 乙醚 、 N,N-二甲基甲酰胺 为溶剂， 反应 48.0h， 生成 1-azido-3,6-dioxa-8-octyl O-(2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyl)-(1->3)-2,4,6-tri-O-acetyl-β-D-galactopyranoside
  参考文献：
  名称：

  Frontal Affinity Chromatography Coupled to Mass Spectrometry: An Effective Method for K_dDetermination and Screening of α‐Gal Derivatives Binding to Anti‐Gal Antibodies (IgG)

  摘要：

  Frontal affinity chromatography with mass spectrometric detection (FAC/MS) was developed as an effective method for rapid determination of K-d values for alpha-Gal derivatives binding to human anti-Gal IgG antibodies. Using this method, K-d values for 23 alpha-Gal compounds were determined for the first time, including an alpha-Gal terminated N-linked oligosaccharide which mimics a single N-glycoform present on the surface of animal cells. A mixture of eight alpha-Gal derivatives, a model for an alpha-Gal compound library, was successfully screened against this anti-Gal IgG using FAC/MS. The analyte breakthrough sequence, indicated by the ion chromatogram, reflected the magnitude of the K-d values, confirming its potential application in the screening of new alpha-Gal derivatives and mimetics. Ten alpha-Gal derivatives were designed and synthesized chemically or enzymatically. Among the compounds analyzed, trivalent compound 26 demonstrated the strongest binding affinity to anti-Gal IgG with a K-d value of 3.1 muM. The alpha-Gal terminated N-linked oligosaccharide 28 had a K-d value of 8.6 muM.

  DOI：

  10.1081/car-120025323
• 作为产物：
  描述：

  1-Chloro-3,6-dioxaoct-8-yl 2,3,4,6-tetra-O-acetyl-β-D-galactopyranoside 在 吡啶 、 4-二甲氨基吡啶 、 ammonium cerium(IV) nitrate 、 二正丁基氧化锡 、 sodium carbonate 作用下， 以 甲醇 、 水 、 乙腈 为溶剂， 反应 51.0h， 生成 1-chloro-3,6-dioxa-8-octyl 2,4,6-tri-O-acetyl-β-D-galactoside
  参考文献：
  名称：

  Frontal Affinity Chromatography Coupled to Mass Spectrometry: An Effective Method for K_dDetermination and Screening of α‐Gal Derivatives Binding to Anti‐Gal Antibodies (IgG)

  摘要：

  Frontal affinity chromatography with mass spectrometric detection (FAC/MS) was developed as an effective method for rapid determination of K-d values for alpha-Gal derivatives binding to human anti-Gal IgG antibodies. Using this method, K-d values for 23 alpha-Gal compounds were determined for the first time, including an alpha-Gal terminated N-linked oligosaccharide which mimics a single N-glycoform present on the surface of animal cells. A mixture of eight alpha-Gal derivatives, a model for an alpha-Gal compound library, was successfully screened against this anti-Gal IgG using FAC/MS. The analyte breakthrough sequence, indicated by the ion chromatogram, reflected the magnitude of the K-d values, confirming its potential application in the screening of new alpha-Gal derivatives and mimetics. Ten alpha-Gal derivatives were designed and synthesized chemically or enzymatically. Among the compounds analyzed, trivalent compound 26 demonstrated the strongest binding affinity to anti-Gal IgG with a K-d value of 3.1 muM. The alpha-Gal terminated N-linked oligosaccharide 28 had a K-d value of 8.6 muM.

  DOI：

  10.1081/car-120025323

文献信息

• Methods and formulations for reducing circulating antibodies
  申请人：——

  公开号：US20010010818A1

  公开（公告）日：2001-08-02

  The invention provides methods for reducing circulating levels of antibodies, particularly disease-associated antibodies. The methods entail administering effective amounts of epitope-presenting carriers to an individual. In other embodiments, ex vivo methods for reducing circulating levels of antibodies are provided which employ epitope-presenting carriers.

  本发明提供了降低循环抗体水平的方法，特别是疾病相关抗体。该方法包括向个体施用有效剂量的表位呈现载体。在其他实施例中，本发明提供了利用表位呈现载体的体外降低循环抗体水平的方法。
• METHODS AND FORMULATIONS FOR REDUCING CIRCULATING ANTIBODIES
  申请人：LA JOLLA PHARMACEUTICAL

  公开号：EP1135167A2

  公开（公告）日：2001-09-26
• CONJUGATES COMPRISING GALACTOSE ALPHA 1,3 GALACTOSYL EPITOPES AND METHODS OF USING SAME
  申请人：LA JOLLA PHARMACEUTICAL

  公开号：EP1137652A2

  公开（公告）日：2001-10-04
• US6399578B1
  申请人：——

  公开号：US6399578B1

  公开（公告）日：2002-06-04
• [EN] METHODS AND FORMULATIONS FOR REDUCING CIRCULATING ANTIBODIES<br/>[FR] PROCEDES ET FORMULATIONS PERMETTANT DE REDUIRE DES ANTICORPS CIRCULANTS
  申请人：JOLLA PHARMA

  公开号：WO2000033887A2

  公开（公告）日：2000-06-15

  The invention provides methods for reducing circulating levels of antibodies, particularly disease-associated antibodies. The methods entail administering effective amounts of epitope-presenting carriers to an individual. In other embodiments, ex vivo methods for reducing circulating levels of antibodies are provided which employ epitope-presenting carriers.